We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
There have been reports of rejection of solid organ transplants in patients treated with nivolumab or pembrolizumab. Ipilimumab (Yervoy▼) may also interfere with immunosuppressive therapy, increasing the risk of graft rejection.
Patients with advanced melanoma are among the first in the world to access pembrolizumab through the early access to medicines scheme (EAMS).
MSD successfully put their advanced new melanoma treatment through MHRA's early access to medicine scheme (EAMS).
Significant clarification of the life-changing EAMS scheme to be introduced into law.
A. Menarini Farmaceutica Internazionale Srl is recalling a specific batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Cases of severe cutaneous adverse reactions, including Stevens-Johnsons syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with immune-stimulatory anti-cancer drugs, including atezolizumab. Advise patients to be vigilant for the signs of severe skin reactions and...
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
Volume 42 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or severe anaemia (a low number of red blood cells...
The process for applicants applying for a Paediatric Investigation Plan (PIP) modification or waiver.
Check the tariff classification for surface-active preparation for washing the skin and the hair (gel 2-in-1).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.